Hovione Technology completes pilot blister manufacturing for the Papillon DPI

November 19th, 2019

Hovione Technology, a pharmaceutical specialist in development of innovative pulmonary device technology, announced today it has completed pilot-scale blister manufacturing and filling for its new reusable blister-based dry powder inhaler, the Papillon DPI. Papillon targets global industry-leading inhaler affordability and environmental sustainability.


"This is an important milestone allowing Hovione Technology to deliver Papillion inhalers together with blister samples to its pharmaceutical partners with their new inhalable powder formulations in quantities suitable for initial development purposes”, said Peter Villax, Hovione Technology’s CEO.


Papillon’s blister is designed to provide flexibility to pharmaceutical partners delivering a wide range of inhaled drugs for both acute and chronic respiratory treatments. Its large cavity size enables filling doses of up to 50 mg and is compatible both with carrier-based and carrier-free powder formulations.


"We are excited to be working with Harro Höfliger, who are experts in powder filling technologies and industrial filling machines to establish a pilot-scale blister manufacturing solution for our Papillon DPI. We will continue to work with this partner to develop a manufacturing solution that can be smoothly integrated into standard, industrial-scale blister filling machines capable of high-volume commercial manufacturing for pharmaceutical partners”, said João Ventura Fernandes, Hovione Technology’s Director of Technology Development and Licensing.

About the PapillonDPI

Hovione Technology’s Papillon dry powder inhaler is an innovative, single-dose reusable blister-based DPI of simple use. Manufactured from a single plastic part, Papillon unlocks a cost of goods perdose competitive to that of multi-dose inhalers at a fraction of the development cost and risk. The Papillon DPI targets global industry-leading inhaler affordability and environmental sustainability

Download:Full Press Release(115.78 KB)
Cookie Policy
This site uses cookies. When browsing the site, you are consenting its use.
Learn more
I understood